EUROIMMUN Medizinische Labordiagnostika AG Sustainability Profile
EUROIMMUN Medizinische Labordiagnostika AG, headquartered in Lübeck, Germany, is a leading player in the field of medical laboratory diagnostics. Founded in 1987, the company has established a strong presence across Europe and beyond, specialising in immunodiagnostics, molecular diagnostics, and laboratory automation. EUROIMMUN is renowned for its innovative products, including a wide range of ELISA tests, immunofluorescence assays, and molecular diagnostic solutions. These offerings are distinguished by their high sensitivity and specificity, catering to various medical fields such as autoimmune diseases, infectious diseases, and allergy testing. With a commitment to quality and research, EUROIMMUN has achieved significant milestones, including numerous certifications and awards that underscore its market position. The company continues to advance diagnostic technology, making it a trusted partner for laboratories worldwide.
DitchCarbon Score
How does EUROIMMUN Medizinische Labordiagnostika AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
EUROIMMUN Medizinische Labordiagnostika AG's score of 43 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
EUROIMMUN Medizinische Labordiagnostika AG, headquartered in Germany, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Revvity, Inc., and any climate commitments or emissions data would be inherited from this parent organisation. As part of its corporate family relationship, EUROIMMUN follows the sustainability initiatives and targets set by Revvity, Inc. However, specific reduction targets or achievements related to carbon emissions have not been disclosed. The absence of documented reduction initiatives or climate pledges suggests that the company may still be in the early stages of formalising its climate strategy. In the context of the industry, it is essential for organisations like EUROIMMUN to align with global climate standards and frameworks, such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), to enhance transparency and accountability in their environmental impact. As the company progresses, it may adopt more robust climate commitments and reduction targets in line with industry best practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,289,000 | 0,000,000 |
| Scope 2 | 29,844,000 | 00,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is EUROIMMUN Medizinische Labordiagnostika AG's Industry?
How Carbon Intensive is EUROIMMUN Medizinische Labordiagnostika AG's Location?
EUROIMMUN Medizinische Labordiagnostika AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
EUROIMMUN Medizinische Labordiagnostika AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
